CORV - Correvio Pharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.0000 (0.00%)
As of 12:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.9400
Bid1.9300 x 900
Ask1.9400 x 1800
Day's Range1.9300 - 1.9900
52 Week Range1.4300 - 5.1500
Avg. Volume130,684
Market Cap97.451M
Beta (3Y Monthly)1.11
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV)

    Is Correvio Pharma Corp. (NASDAQ:CORV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]

  • Associated Press

    Correvio: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 23 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...

  • Zacks Small Cap Research

    CORV: Topline Growth Accelerating

    Loss per share was ($0.20) as SG&A expenses grew reflecting an increase in the sales force. Newsflow during the third quarter continued to be very positive for Brinavess, and management has guided to a 2Q:19 resubmission to the FDA. Trevyent is now in the hands of United Therapeutics (UTHR) following their acquisition of SteadyMed.

  • Zacks Small Cap Research

    CORV: Brinavess Continues to Hit Milestones

    2018 has been an exciting year for Correvio Pharma Corp. (CORV) (CORV.TO), with several transformative events taking place. Brinavess continues to achieve milestones with the recent conclusion of the pre-NDA meeting, confirmation of the timeline for FDA action and receipt of an opinion regarding an extension of the patent term. The most exciting news for the year was the FDA’s announcement regarding the resubmission of Brinavess and the scheduling of a pre-NDA meeting.

  • Zacks Small Cap Research

    CORV: Brinavess Continues to Lead

    Correvio Pharma Corp. (CORV) has had an exciting year for Brinavess so far in 2018. While it received EMA regulatory approval in 2010, it was not given the go ahead in the United States and has been on hold with the FDA ever since. Despite the hold, things have begun to turn in favor of Brinavess on several fronts.

  • Investopedia

    Penny Stocks to Watch for September 2018

    Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.